A Pharmacogenomics Study of TAS-102

A Pharmacogenomics Study of TAS-102 with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Status

Unknown

Phases

Phase 3

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2080221873

Enrollment

266

Registered

2012-08-02

Start date

2012-08-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

investigational material(s) Generic name etc : TAS-102 INN of investigational material : Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum

Exclusion criteria

Exclusion criteria: - Has received TAS-102

Design outcomes

Primary

Measure	Time frame
Correlation between the relative factor and disease control rate, overall survival, or progression-free survival RECIST (ver.1.1)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026